Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
274 studies found for:    "systemic scleroderma"
Show Display Options
Download search resultsDownload the search results for:
"systemic scleroderma" (274 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed
Has Results
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
Condition: SYSTEMIC SCLERODERMA
Interventions: Drug: standard of care;   Procedure: stem cell transplantation
2 Completed Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Condition: Systemic Scleroderma
Interventions: Drug: C-82 Topical Gel, 1%;   Drug: C-82 Topical Gel, Placebo
3 Withdrawn Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: rituximab;   Drug: cyclophosphamide;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
4 Completed Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
Condition: Systemic Scleroderma
Interventions: Drug: Sildenafil;   Drug: placebo
5 Completed Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
Condition: Systemic Scleroderma
Intervention: Procedure: standardized reeducation and readaptation program
6 Recruiting Scleroderma Treatment With Autologous Transplant (STAT) Study
Condition: Systemic Scleroderma
Interventions: Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
7 Recruiting Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Conditions: Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
8 Terminated Immunoadsorption in Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Intervention: Device: TheraSorb Ig
9 Recruiting Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
Intervention:
10 Recruiting Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
Condition: Scleroderma
Interventions: Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
11 Recruiting Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
Conditions: SYSTEMIC SCLERODERMA;   ALLOGENEIC MESENCHYMAL STEM CELLS;   ADULT
Intervention: Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
12 Unknown  Nilotinib in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Nilotinib (Tasigna)
13 Active, not recruiting Taking Charge of Systemic Sclerosis
Condition: Scleroderma
Interventions: Other: Internet-based self-management program;   Other: Scleroderma book
14 Completed Morbidity and Mortality Follow Up for the Scleroderma Lung Study
Condition: Scleroderma
Intervention: Other: Followup survey
15 Unknown  Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Imatinib Mesylate
16 Completed Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:
17 Recruiting Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
Condition: Scleroderma
Intervention: Drug: Campath
18 Terminated Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Thalidomide;   Drug: Placebo thalidomide
19 Completed Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:
20 Recruiting Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: atorvastatin;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.